EP Patent

EP0813870A1 — Use of darifenacin to enhance cognitive functions

Assigned to Novartis International Pharmaceutical Ltd · Expires 1997-12-29 · 28y expired

What this patent protects

Darifenacin, and its pharmaceutically acceptable salts, are useful in the treatment of cognitive impairment. The invention also discloses the use of combinations of darifenacin, or a pharmaceutically acceptable salt thereof, with an acetylcholinesterase inhibitor, in the tr…

USPTO Abstract

Darifenacin, and its pharmaceutically acceptable salts, are useful in the treatment of cognitive impairment. The invention also discloses the use of combinations of darifenacin, or a pharmaceutically acceptable salt thereof, with an acetylcholinesterase inhibitor, in the treatment of cognitive impairment.

Drugs covered by this patent

Patent Metadata

Patent number: EP0813870A1
Jurisdiction: EP
Classification: —
Expires: 1997-12-29
Drug substance claim: No
Drug product claim: No
Assignee: Novartis International Pharmaceutical Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.